# An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Source: https://onco.cc/trials/nct02180724/  
OnCo record `nct02180724` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib in waldenström macroglobulinaemia, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT02180724 by Acerta Pharma BV, with 107 participants enrolled, started 2014-09-11 and due to reach its primary completion in 2019-10-01. Interventions recorded: Acalabrutinib (ACP-196). Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02180724
- Phase: 2
- Setting: An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
- Sponsor: Acerta Pharma BV
- Enrolled: 107

## Sources

- ClinicalTrials.gov NCT02180724: https://clinicaltrials.gov/study/NCT02180724

## Connected records

- cancers: [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02180724.json